Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $44
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $42 to $44.
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $42 to $44.